Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
The first consensus paper on atrial cardiomyopathies is set to be published simultaneously in EP-Europace, HeartRhythm, and the Journal of Arrhythmia. The key contents are launched today at CARDIOSTIM - EHRA EUROPACE 2016
The first consensus paper on atrial cardiomyopathies is set to be published simultaneously in EP-Europace, HeartRhythm, and the Journal of Arrhythmia. The key contents are launched today at CARDIOSTIM - EHRA EUROPACE 2016.1The report was written by a working group of the European Heart Rhythm Association (EHRA) which is a registered branch of the European Society of Cardiology (ESC), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE).
Professor Andreas Goette, chair of the working group, said: “Atrial cardiomyopathies contribute to the development of atrial fibrillation, which is the most common heart rhythm disturbance. They can also lead to atrial clots and consequent stroke, and therefore have substantial clinical significance.”
He continued: “There are multiple papers on ventricular cardiomyopathies but until now, no consensus was reached about atrial cardiomyopathies. This is a global consensus paper and an important step forward for research and treatment in this field.”The document contains the first definition and classification of atrial cardiomyopathies. The definition states that atrial cardiomyopathy is “any complex of structural, architectural, contractile or electrophysiological changes affecting the atria with the potential to produce clinically relevant manifestations”.The novel classification scheme, called EHRAS (EHRA/HRS/APHRS/SOLAECE), denotes four classes based on histological and pathological findings including cardiomyocyte changes, fibrosis, and non-collagen infiltration.“This is the first attempt to separate atrial pathologies into discrete groups,” said Professor Goette. “It can be used to describe the underlying pathology in various clinical conditions. Ultimately it should help us to tailor therapies for atrial fibrillation based on the underlying cause, which might improve patient outcomes.”The paper outlines the triggers of atrial fibrillation. These include mutations, congestive heart failure, obstructive sleep apnoea, medications, aging, hypertension, obesity, and diabetes. Advice is given on how to prevent or delay the occurrence of atrial fibrillation.Controversies surrounding the mechanism of atrial fibrillation are discussed. One theory is that fibrillation results from the continued random propagation of multiple independent electric waves that move independently throughout the atria. The opposing view is that fibrillation is a consequence of the continued activity of a few vortices (rotors) that spin at high frequencies. Regardless of the mechanism that maintains it, sustained atrial fibrillation leads to electrical remodelling that is reversible in the short term but not if it lasts for months or years.Professor Goette said: “Ongoing investigations into the mechanisms will stimulate improved treatment and prevention.”The paper addresses the potential use of biomarkers to predict atrial fibrillation and stroke risk. The authors state that “The clinical benefit of considering biomarkers associated with atrial fibrillation is questionable” and there is limited evidence for their added value in stroke risk prediction.Finally, advice is given on the use of imaging to screen and follow patients with atrial cardiomyopathies. For example, echocardiography is the modality of choice for screening and following patients with diseases involving left atrial morphology and function. Cardiac computed tomography can be used to screen for thrombus before ablation of atrial fibrillation.Professor Goette said: “More research is needed to correlate EHRAS classes I–IV with imaging findings to help us better characterise atrial cardiomyopathies. This could have large clinical implications because patients with various degrees of myopathy might be treated differently.”He concluded: “Atrial fibrillation stems from a number of causes. Here we define and classify the different atrial pathologies so that ultimately, patients can be given individualised treatment that gives them the best possible outcome.”
© 2017 European Society of Cardiology. All rights reserved